Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07243275
PHASE4

SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease

Sponsor: Indiana University

View on ClinicalTrials.gov

Summary

This is a prospective, randomized, double-masked, multi-site clinical trial designed to compare the efficacy of SYSTANE® PRO (Alcon Laboratories, Inc.) to MIEBO™ (Bausch + Lomb) in treating symptoms of evaporative dry eye disease (DED). The primary goal is to determine whether SYSTANE® PRO is non-inferior to MIEBO™ after one month of treatment, based on change in Ocular Surface Disease Index (OSDI) scores.

Official title: Comparing the Efficacy of SYSTANE® PRO to MIEBO™ for the Treatment of Dry Eye Disease

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

260

Start Date

2026-02-18

Completion Date

2026-09-30

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

DRUG

SYSTANE® PRO

SYSTANE® PRO is a preservative free artificial tear with a unique triple action formula that contains hyaluronate, nano-sized lipids, and HP-Guar.

DRUG

MIEBO™ (Perfluorohexyloctane, PFHO)

Perfluorohexyloctane (PFHO) ophthalmic solution, which is marketed in the United States as MIEBO™ (Bausch + Lomb; Rochester, NY, USA) is a preservative-free eye drop.

Locations (4)

Eye Research Foundation

Newport Beach, California, United States

Indiana Universtiy School of Optometry

Bloomington, Indiana, United States

Kannarr Eye Care

Pittsburg, Kansas, United States

Southern College of Optometry

Memphis, Tennessee, United States